Gadoterate meglumine

Drug #2309

Gadoterate meglumine is a paramagnetic macrocyclic ionic contrast agent administered for magnetic resonance imaging. The chemical name for gadoterate meglumine is D-glucitol, 1-deoxy-1-(methylamino)-, [1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraaceto(4-)-.kappa.N1, .kappa.N4, .kappa.N7, .kappa.N10, .kappa.O1,.kappa.O4, .kappa.O7, .kappa.O10]gadolinate(1-)(1:1);It is indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or anormal vascularity.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Gadoterate meglumine.

It belongs to Radiopaque Agents pharmacological group on the basis of mechanism of action.

Molecular Weight: 753.9 · Solubility in Water: soluble · Non-proprietary name: Gadoterate meglumine.

Molecular structure of Gadoterate meglumine

Pharmacokinetics

Distribution: Gadoterate meglumine has a volume of distribution is 0.246 ± 0.03l/kg.

Elimination: plasma half-life is 1.6 ± 0.2 hrs, renal excretion is 72.9 ± 17.0% in urine.

Indications

Gadoterate meglumine is primarily indicated in conditions like Radiological contrast agent.

Contraindications

None recorded.

Dosage

Gadoterate meglumine's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.2 mL/kg	0.2 mL/kg	—	IV bolus injection	at a flow rate of approximately 2mL/sec for adult
Paediatric Dosage (20kg)
0 – 0.2 mL/kg	—	—	IV	at a flow rate of 1-2mL/sec for paediatrics patients
Neonatal Dosage (3kg)
No data.

Drug Interactions

None recorded.

Side Effects

Gadoterate meglumine is known to cause more or less tolerable side effects which are usually transient. These include Buring Secration, Headache, injection site coldness, injection site pain, Nausea.

Warnings / Precautions

Nephrogenic Systemic Fibrosis has occurred in patients with impaired elimination of GBCAs. Higher than recommended dosing or repeat dosing appear to increase the risk. • Hypersensitivity: Anaphylactoid/anaphylactic reactions with cardiovascular, respiratory or cutaneous manifestations, ranging from mild to severe, including death, have uncommonly occurred. Monitor patients closely for need of emergency cardiorespiratory support

Available Brands

None recorded.

Storage Conditions

Gadoterate meglumine should be stored injection.

Drug Classification

1.14.2 — Radiocontrast media